Iressa black box sought
Executive Summary
Public Citizen requests that FDA add a black box warning to Iressa labeling "to state that the drug should be reserved for the same group of patients who were studied in the Phase II trial on which approval was based." FDA approved AstraZeneca's Iressa (gefitinib) for the treatment of advanced non-small cell lung cancer May 5 (1"The Pink Sheet" May 12, p. 3). A black box warning should communicate to "patient[s] that they may be at risk of a fatal lung disease unrelated to NSCLC," Public Citizen says in May 15 letter to Commissioner McClellan. FDA was understood to be considering a black box warning until very late in the review cycle for the drug...
You may also be interested in...
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.